Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.
Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
The Food and Drug Administration on Wednesday approved a new treatment for people with non-small cell lung cancer that contains a rare genetic alteration called
November 16, 2023